Inovio Pharmaceuticals, Inc. (INO) Q2 2023 Earnings Call Transcript

SA Transcripts
153.96K Followers

Q2: 2023-08-09 Earnings Summary

EPS of -$1.56 beats by $0.18
 | Revenue of $225.97K (-71.19% Y/Y) misses by $36.53K

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET

Company Participants

Thomas Hong - Manager of Investor Relations
Jacque Shea - President and Chief Executive Officer
Michael Sumner - Chief Medical Officer
Peter Kies - Chief Financial Officer

Conference Call Participants

Roger Song - Jefferies
Hartaj Singh - Oppenheimer
Dipesh Patel - H.C. Wainwright

Operator

Good day, and welcome to the Inovio Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead.

Thomas Hong

Good afternoon, and thank you for joining the Inovio 2023 second quarter conference call.

Joining me on today's call are Dr. Jacque Shea, President and CEO; Dr. Michael Sumner, Chief Medical Officer; and Mr. Peter Kies, Chief Financial Officer.

Today's call will review our corporate and financial information for the quarter ended June 30, 2023, as well as provide a development progress update for our DNA medicines platform. Following prepared remarks, we will conduct a question-and-answer segment.

During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today.

Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors identify important factors that could

Recommended For You

About INO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on INO